MannKind Accelerates Growth with $500M Blackstone Deal and scPharmaceuticals Merger

Introduction

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on developing and commercializing inhalable therapeutic products and devices for individuals with endocrine and orphan lung diseases. Founded in February 1991 and headquartered in Danbury, Connecticut, MannKind utilizes its proprietary Technosphere® dry-powder technology to facilitate the rapid delivery of medications to the deep lung.

Corporate Structure and Workforce

MannKind employs approximately 425 individuals across its key locations:

• Danbury, Connecticut (headquarters and Afrezza® manufacturing facility)
• Bedford, Massachusetts (research and development hub)
• Westlake Village, California (corporate office)

The company is organized into various functional areas, including research & development, manufacturing & engineering, commercial operations, quality assurance, and corporate support functions (HR, finance, legal, communications, business development, and IT).

Inhalable insulin by diabetesmagazijn.nl

Recent Developments and News

• December 11, 2024: India's Central Drugs Standard Control Organization approved Afrezza® (insulin human) Inhalation Powder for distribution through Cipla Ltd., with shipments expected by the end of 2025.
• December 16, 2024: Six-month data from the Phase 3 INHALE-1 pediatric diabetes trial were released. MannKind plans to engage with the U.S. Food and Drug Administration in the first half of 2025 to discuss a supplemental New Drug Application.
• November 7, 2024: Third-quarter 2024 revenues totaled $70.0 million, marking a 37% increase year-over-year. Year-to-date revenues reached $209.0 million, up 49% compared to the first nine months of 2023. Year-to-date net income was reported at $20.0 million (non-GAAP net income of $45.0 million).
• August 24, 2025: MannKind signed a definitive merger agreement to acquire scPharmaceuticals, aiming to expand into cardiometabolic and chronic care markets.
• August 25, 2025: A Schedule TO-C filing outlined the terms of the tender offer for scPharmaceuticals, including regulatory and integration risks.
• August 27, 2025: MannKind filed a Form 8-K under Items 1.01 and 9.01, disclosing material agreements related to the scPharmaceuticals transaction.
• August 2025: The company secured up to $500 million in non-dilutive strategic financing from Blackstone to support commercial expansion, pipeline advancement, and general corporate initiatives.
• September 2, 2025: Shares closed at $6.27 on Nasdaq, reflecting a 36.60% increase on trading volume of 2,364,508 shares.
• September 2025: The CEO and CFO are scheduled for presentations at investor conferences in Boston and New York, discussing the cardiometabolic business, orphan lung pipeline progression, and pediatric applications of Afrezza®.
• Partnership Expansion: MannKind extended its collaboration with United Therapeutics to include the formulation of a second inhaled therapy.

Financial and Strategic Analysis

MannKind’s third-quarter 2024 results demonstrated significant growth in both quarterly and year-to-date revenues, primarily driven by sales of Afrezza® and initiatives related to orphan lung disease programs. The $500 million financing agreement with Blackstone provides non-dilutive capital to support the expansion of the commercial team, advance the pipeline, and pursue strategic acquisitions. The planned acquisition of scPharmaceuticals is expected to introduce the FUROSCIX autoinjector product line, aiding MannKind’s entry into cardiometabolic markets and diversifying its revenue streams. The share price increase on September 2, 2025, may indicate market acknowledgement of these strategic initiatives.

Market Position and Industry Context

MannKind operates within the inhalation drug-delivery sector, distinguished by its Technosphere® platform that underlies Afrezza®, recognized as the only rapid-acting inhalable insulin approved in the U.S. Its development pipeline includes treatments for pulmonary arterial hypertension and nontuberculous mycobacterial lung disease. The company’s collaborative approach includes partnerships with Cipla for global distribution, United Therapeutics for R&D, and strategic financing from Blackstone. The intended acquisition of scPharmaceuticals will further position MannKind in the inhalation and autoinjector therapeutic markets focusing on cardiometabolic and chronic care.

tl;dr

• MannKind signed a merger agreement for scPharmaceuticals on August 24, 2025, with a tender offer filed on August 25 and detailed in Form SC TO-C.
• A Form 8-K on August 27, 2025, disclosed material agreements supporting the acquisition.
• In August 2025, MannKind secured up to $500 million in non-dilutive financing from Blackstone.
• On September 2, 2025, shares closed at $6.27, up 36.60% with 2.36 million shares traded.
• A meeting with the FDA is planned for the first half of 2025, following Phase 3 pediatric data announced on December 16, 2024.
• Afrezza® received approval in India on December 11, 2024, with shipments expected by late 2025.